Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€43.20

€43.20

1.310%
0.56
1.310%
€21.47
 
07.04.26 / Tradegate WKN: A2N9D9 / Symbol: MRNA / Name: Moderna / Stock / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Moderna Inc. Stock

There is an upward development for Moderna Inc. compared to yesterday, with an increase of €0.56 (1.310%).
With 7 Buy predictions and 8 Sell predictions the community is currently undecided on Moderna Inc..
The target price of 21 € compared with the current price of 43.2 € for the stock indicates a negative potential of -51.38%.
For the coming years our community has positive and negative things to say abot the Moderna Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.

Pros and Cons of Moderna Inc. in the next few years

Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-03

From a general perspective, Moderna's financials reveal a solid growth trajectory, with the company experiencing significant improvements across various financial metrics. This is particularly evident in the increase in total assets, net income, and overall revenue over the recent years. Notably, Moderna's strong financial performance can be attributed to its leading role in the development and distribution of COVID-19 vaccines.

*Pros: *

Expanding revenue: Moderna has witnessed a remarkable growth in total revenue, particularly in the years 2021 and 2022. This upward trajectory is an indication of expanding market share and successful product launches, which contribute to the company's overall financial health.

Comments

Prediction Buy
Perf. (%) 2.85%
Target price 58.333
Change
Ends at 23.02.27

Moderna (NASDAQ:MRNA) had its price target raised by analysts at Piper Sandler from $63.00 to $69.00. They now have an "overweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Show more

Moderna (NASDAQ:MRNA) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to a "buy" rating.
Ratings data for MRNA provided by MarketBeat
Show more

Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Ratings data for MRNA provided by MarketBeat
Show more

News

2 Healthcare Stocks That Could Soar Over the Next 5 Years: https://g.foolcdn.com/editorial/images/861666/scientist-altering-dna-genome-project.jpg
2 Healthcare Stocks That Could Soar Over the Next 5 Years

While the stock market is facing significant volatility right now, there is a decent chance it will still perform fairly well over the next five years. That's what we have come to expect from

Moderna Stock is Soaring. Is It Too Late to Buy?: https://g.foolcdn.com/editorial/images/862087/gettyimages-1370880932-1200x800-5b2df79.jpg
Moderna Stock is Soaring. Is It Too Late to Buy?

Moderna (NASDAQ: MRNA) is best known for its coronavirus vaccine, a product that generated more than $18 billion in revenue at its peak in 2022 and helped drive the stock higher during the early

The S&P 500's 3 Best-Performing Stocks so far in 2026
The S&P 500's 3 Best-Performing Stocks so far in 2026

Fear is dominating global markets right now. With geopolitical tensions intensifying in the Middle East and capital rotating out of equities, the S&P 500 ETF (NYSEARCA: SPY) is down about 2% year